CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性大 B 细胞淋巴瘤 CAR-T 治疗后迟发性孤立性中枢神经系统复发三例
英文原题：Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma.
查看英文原题
Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向CD19的CAR-T 细胞治疗显著改善了复发/难治性大B细胞淋巴瘤患者的结局，但约50%的患者仍会在治疗后复发。CAR-T 治疗失败病例中约三分之一至二分之一为迟发复发，此前尚无免疫豁免部位孤立复发的报道。本文首次报告系统性复发/难治性大B细胞淋巴瘤患者CAR-T 治疗后迟发性孤立中枢神经系统（CNS）复发的病例系列。根据这些病例，作者建议，对既往有神经系统受累、多发结外病灶、CAR-T 治疗前CNS-IPI评分较高，且输注后循环CAR-T 细胞过早消失的原发难治患者，应考虑加强CNS预防治疗。
展开英文摘要原文
CD19-chimeric antigen receptor T-cell (CAR T-cell) therapy has improved the outcomes of relapsed/refractory large B cell lymphoma significantly.
However, about 50% of patients relapsed post-CAR-T therapy. Late relapse composed of 1/3 to 1/2 of CAR-T cell therapy failure, with no previous reports of isolated relapse in immune-privileged sites.
Here, we report the first case series of late-onset post CAR-T cell therapy isolated central nervous system (CNS) relapses, in systemic relapsed/refractory large B cell lymphoma patients. With these cases, we suggest that additional CNS prophylaxis should be administrated for primary refractory patients on CAR-T cell therapy with previous neurological involvements, multiple extra-nodular lesions, and high CNS-IPI score pre-CAR, as well as early disappearance of circulating CAR-T cells post infusion.
论文信息
- 作者
- Zhu H、Zhuang Z、Wang W、Zhao D、Zhang W、Zhou D、Zhang Y
- 单位
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.China
- 文献类型
- 病例报告
- 期刊
- European journal of haematology2024 Feb
- 原文标识
- PubMed 37723652 · DOI 10.1111/ejh.14078